AKT1 and acute myeloid leukemia: In conclusion, the frequent mutational activation of PI3K/AKT signaling in AML patients, as well as its prominent role in therapy resistance, provides a rationale for targeted inhibition of PI3K/AKT signaling to enhance the efficacy of standard AML therapies and ultimately overcome therapy resistance.